CCNB1 is a prognostic biomarker for ER+ breast cancer

Medical Hypotheses

Volumn 83, Issue 3, 2014, Pages 359-364

  Ding, Kun ^a   Li, Wenqing ^a   Zou, Zhiqiang ^a   Zou, Xianzhi ^a   Wang, Chengru ^a  

^a Yantai City Hospital for Infectious Disease   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CISPLATIN; CYCLIN B1; DOXORUBICIN; ESTROGEN RECEPTOR; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CCNB1 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; HORMONE; MESSENGER RNA; TUMOR MARKER;

ARTICLE; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; DRUG PROTEIN BINDING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; RECURRENCE FREE SURVIVAL; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOMICS; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; PROGNOSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CYCLIN B1; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HORMONES; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM METASTASIS; PROGNOSIS; RNA, MESSENGER; TAMOXIFEN;

EID: 84908356032     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.06.013     Document Type: Article

References (46)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 2008, 127(2893-2917):2010.
2. Vendrell J.A., Ghayad S., Ben-Larbi S., Dumontet C., Mechti N., Cohen P.A. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene 2007, 26:4656-4667. Epub 2007 Feb 4612.
3. Miller W.R. Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. J Steroid Biochem Mol Biol 2010, 118:273-276.
4. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002, 360:1131-1135.
5. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Senn H.J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Primary breast cancer. J Clin Oncol 2001, 19:3817-3827.
6. Eifel P., Axelson J.A., Costa J., et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001, 93:979-989.
7. Group EBCTC Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351:1451-1467.
8. Group EBCTC Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 352:930-942.
9. Bergh J. Where next with stem-cell-supported high-dose therapy for breast cancer?. Lancet 2000, 355:944-945.
10. Group EBCTC Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2000, 355:1757-1770.
11. Clarke R., Liu M.C., Bouker K.B., et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003, 22:7316-7339.
12. Osborne C.K., Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 2003, 12:362-367.
13. Miyazaki T., Arai S. Two distinct controls of mitotic cdk1/cyclin B1 activity requisite for cell growth prior to cell division. Cell Cycle 2007, 6:1419-1425.
14. Takizawa C.G., Morgan D.O. Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol 2000, 12:658-665.
15. Uhlen M., Oksvold P., Fagerberg L., et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010, 28:1248-1250. doi: 1210.1038/nbt1210-1248.
16. Song Y., Zhao C., Dong L., et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis. Carcinogenesis 2008, 29:307-315.
17. Jirstrom K., Stendahl M., Ryden L., et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005, 65:8009-8016.
18. Taminau J., Meganck S., Lazar C., et al. Unlocking the potential of publicly available microarray data using in Silico Db and inSilicoMerging R/Bioconductor packages. BMC Bioinformatics 2012, 13:335. 10.1186/1471-2105-1113-1335.
19. Ur-Rehman S., Gao Q., Mitsopoulos C., Zvelebil M. ROCK: a resource for integrative breast cancer data analysis. Breast Cancer Res Treat 2013, 139:907-921. doi: 910.1007/s10549-10013-12593-z. Epub 12013 Jun 10512.
20. Gyorffy B., Lanczky A., Eklund A.C., et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat 2010, 123:725-731. doi: 710.1007/s10549-10009-10674-10549. Epub 12009 Dec 10518.
21. Miller L.D., Smeds J., George J., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555. Epub 12005 Sep 13552.
22. Gonzalez-Malerva L., Park J., Zou L., et al. High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci USA 2010, 108:2058-2063. doi: 2010.1073/pnas.1018157108. Epub 1018152011 Jan 1018157113.
23. Subramanian A., Tamayo P., Mootha V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550. Epub 12005 Sep 15530.
24. Davis A.P., Wiegers T.C., Johnson R.J., et al. Text mining effectively scores and ranks the literature for improving chemical-gene-disease curation at the comparative toxicogenomics database. PLoS ONE 2013, 8:e58201. doi: 58210.51371/journal.pone.0058201. Print 0052013.
25. Shannon P., Markiel A., Ozier O., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13:2498-2504.
26. Castellano I., Chiusa L., Vandone A.M., et al. A simple and reproducible prognostic index in luminal ER-positive breast cancers. Ann Oncol 2013, 24(2292-2297):22. doi: 2210.1093/annonc/mdt2183. Epub 24, 2013.
27. Collaborative EBCT and Group EBCTC Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
28. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388.
29. Palmieri C., Patten D.K., Januszewski A., Zucchini G., Howell S.J. Breast cancer: current and future endocrine therapies. Mol Cell Endocrinol 2013, 7:324-329.
30. Ma X.J., Wang Z., Ryan P.D., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5:607-616.
31. Jansen M.P., Foekens J.A., van Staveren I.L., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005, 23:732-740.
32. Oh D.S., Troester M.A., Usary J., et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006, 24:1656-1664.
33. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
34. Ruckhaberle E., Holtrich U., Engels K., et al. Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer. Climacteric 2009, 12:502-513. doi: 510.3109/13697130902939913.
35. Xu X.L., Chen S.Z., Chen W., et al. The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis. Breast Cancer Res Treat 2013, 139:329-339. doi: 310.1007/s10549-10013-12563-10545. Epub 12013 May 10514.
36. Yamamoto M., Hosoda M., Nakano K., et al. P53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci 2013, 10:12302.
37. Johansson H.J., Sanchez B.C., Mundt F., et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun 2013, 4:2175. 10.1038/ncomms3175.
38. Guo S., Li Y., Tong Q., et al. DeltaEF1 down-regulates ER-alpha expression and confers tamoxifen resistance in breast cancer. PLoS ONE 2012, 7:e52380. 52310.51371/journal.pone.0052380. Epub 0052012 Dec 0052321.
39. Hiscox S., Baruha B., Smith C., et al. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer 2012, 12:458. 10.1186/1471-2407-1112-1458.
40. Piva M., Domenici G., Iriondo O., et al. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med 2013, 31:201303411.
41. Loh Y.N., Hedditch E.L., Baker L.A., Jary E., Ward R.L., Ford C.E. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer 2013, 13:174. 10.1186/1471-2407-1113-1174.
42. Korenaga D., Takesue F., Yasuda M., Honda M., Nozoe T., Inutsuka S. The relationship between cyclin B1 overexpression and lymph node metastasis in human colorectal cancer. Surgery 2002, 131:S114-S120.
43. Hassan K.A., Ang K.K., El-Naggar A.K., et al. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 2002, 62:6414-6417.
44. Patil G.B., Hallikeri K.S., Balappanavar A.Y., Hongal S.G., Sanjaya P.R., Sagari S.G. Cyclin B1 overexpression in conventional oral squamous cell carcinoma and verrucous carcinoma- A correlation with clinicopathological features. Med Oral Patol Oral Cir Bucal 2013, 18:e585-s590.
45. Huang V., Place R.F., Portnoy V., et al. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res 2012, 40:1695-1707.
46. Lu M., Breyssens H., Salter V., et al. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell 2013, 23:618-633.